PL2648516T3 - Podstawione związki pirydynono-pirydynylowe - Google Patents
Podstawione związki pirydynono-pirydynyloweInfo
- Publication number
- PL2648516T3 PL2648516T3 PL11847595T PL11847595T PL2648516T3 PL 2648516 T3 PL2648516 T3 PL 2648516T3 PL 11847595 T PL11847595 T PL 11847595T PL 11847595 T PL11847595 T PL 11847595T PL 2648516 T3 PL2648516 T3 PL 2648516T3
- Authority
- PL
- Poland
- Prior art keywords
- pyridinyl compounds
- substituted pyridinone
- pyridinone
- substituted
- pyridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42007410P | 2010-12-06 | 2010-12-06 | |
| PCT/US2011/063608 WO2012078684A1 (en) | 2010-12-06 | 2011-12-06 | Substituted pyridinone-pyridinyl compounds |
| EP11847595.3A EP2648516B1 (en) | 2010-12-06 | 2011-12-06 | Substituted pyridinone-pyridinyl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2648516T3 true PL2648516T3 (pl) | 2019-04-30 |
Family
ID=46162793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11847595T PL2648516T3 (pl) | 2010-12-06 | 2011-12-06 | Podstawione związki pirydynono-pirydynylowe |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20120142709A1 (pl) |
| EP (2) | EP3469907B1 (pl) |
| JP (1) | JP5848775B2 (pl) |
| CN (1) | CN103391718A (pl) |
| CA (1) | CA2819889C (pl) |
| DK (1) | DK2648516T3 (pl) |
| ES (2) | ES2697607T3 (pl) |
| HR (1) | HRP20181788T1 (pl) |
| HU (1) | HUE040101T2 (pl) |
| PL (1) | PL2648516T3 (pl) |
| PT (1) | PT2648516T (pl) |
| SI (1) | SI2648516T1 (pl) |
| WO (1) | WO2012078684A1 (pl) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054178T2 (hu) | 2013-06-07 | 2021-08-30 | Aclaris Therapeutics Inc | Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek |
| CN104860932B (zh) * | 2015-05-13 | 2018-01-12 | 安阳师范学院 | 一种吡唑啉酮类化合物及其应用 |
| CN104892499B (zh) * | 2015-06-26 | 2017-07-21 | 江西省科学院应用化学研究所 | 一种2‑吡啶酮类衍生物的合成方法 |
| MX387359B (es) * | 2017-03-16 | 2025-03-18 | Bristol Myers Squibb Co | Inhibidores de cinasa activada por mitógeno 2 (mk2), síntesis de los mismos, e intermediarios de los mismos. |
| PH12022550029A1 (en) * | 2019-07-31 | 2023-02-27 | Aclaris Therapeutics Inc | Deuterated mk2 pathway inhibitors and methods of using the same |
| CN115484952B (zh) * | 2020-03-27 | 2024-10-18 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡啶酮-吡啶基化合物的方法、组合物和结晶形式 |
| CN116685322A (zh) * | 2020-11-23 | 2023-09-01 | 阿克拉瑞斯治疗股份有限公司 | 合成被取代的吡啶酮-吡啶基化合物的方法 |
| KR20230112696A (ko) * | 2020-11-23 | 2023-07-27 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 합성 방법 |
| EP4313970A4 (en) * | 2021-03-31 | 2025-06-25 | Xinthera, Inc. | MK2 INHIBITORS AND THEIR USES |
| AU2022307534B2 (en) | 2021-07-09 | 2025-12-04 | Xinthera, Inc. | Pyridinone mk2 inhibitors and uses thereof |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| TW202315625A (zh) * | 2021-08-13 | 2023-04-16 | 大陸商深圳信立泰藥業股份有限公司 | 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途 |
| TWI836822B (zh) * | 2021-12-29 | 2024-03-21 | 大陸商上海美悦生物科技發展有限公司 | p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途 |
| TWI866007B (zh) * | 2021-12-29 | 2024-12-11 | 大陸商上海美悦生物科技發展有限公司 | p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| KR20240134978A (ko) | 2022-01-14 | 2024-09-10 | 상하이 한서 바이오메디컬 컴퍼니 리미티드 | 피리딘 함유 폴리시클릭 유도체, 이의 제조 방법 및 용도 |
| WO2023134765A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含五元环类衍生物、其制备方法和应用 |
| WO2023150709A2 (en) * | 2022-02-04 | 2023-08-10 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| CN117800948A (zh) * | 2022-05-12 | 2024-04-02 | 上海美悦生物科技发展有限公司 | 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途 |
| WO2024022412A1 (zh) * | 2022-07-28 | 2024-02-01 | 深圳信立泰药业股份有限公司 | 一种式(i)所示的三联吡啶二酮化合物晶型及其制备方法与应用 |
| CN119053588A (zh) * | 2022-08-30 | 2024-11-29 | 长春金赛药业有限责任公司 | p38α-MK2抑制剂化合物、药物组合物及其应用 |
| TW202428271A (zh) * | 2022-11-16 | 2024-07-16 | 大陸商上海美悦生物科技發展有限公司 | 吡啶氮氧化物類衍生物及其藥物組合物、製備方法和用途 |
| WO2024149359A1 (zh) * | 2023-01-13 | 2024-07-18 | 上海美悦生物科技发展有限公司 | 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途 |
| WO2025092739A1 (zh) * | 2023-10-30 | 2025-05-08 | 浙江星浩澎博医药有限公司 | 二氢苯并呋喃类衍生物、其制备方法和用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526482A (ja) | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| CN1310906C (zh) | 1999-05-21 | 2007-04-18 | 肖斯公司 | 用作p38激酶抑制剂的吲哚类型的衍生物 |
| MXPA02012314A (es) * | 2000-06-12 | 2004-09-06 | Eisai Co Ltd | Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos. |
| WO2002042292A2 (en) | 2000-11-20 | 2002-05-30 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
| US7314752B2 (en) | 2001-07-19 | 2008-01-01 | Common Sense, Ltd. | Secretion-monitoring article |
| PL370636A1 (pl) * | 2001-11-22 | 2005-05-30 | Ono Pharmaceultical Co, Ltd. | Pochodne piperydyn-2-onu i farmaceutyczna kompozycja zawierająca te związki jako aktywny składnik |
| DE60333166D1 (de) * | 2002-02-13 | 2010-08-12 | Hoffmann La Roche | Pyridin- und pyrimidin-derivate |
| ES2334990T3 (es) * | 2002-02-14 | 2010-03-18 | Pharmacia Corporation | Piridinonas sustituidas como moduladores de p38 map quinasa. |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| GB0218630D0 (en) | 2002-08-10 | 2002-09-18 | Tanabe Seiyaku Co | Novel compounds |
| EP1549315A4 (en) | 2002-09-11 | 2007-05-23 | Merck & Co Inc | DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| CL2004002050A1 (es) * | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| JP2005255675A (ja) | 2004-02-09 | 2005-09-22 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| KR20070002006A (ko) | 2004-02-11 | 2007-01-04 | 스미스클라인 비참 코포레이션 | Ｈｉｖ 인테그라제 억제제 |
| WO2005105743A1 (ja) * | 2004-04-28 | 2005-11-10 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| BRPI0607913A2 (pt) | 2005-04-08 | 2010-03-23 | Eisai R&D Man Co Ltd | agente terapÊutico para discinesia |
| TW200740755A (en) | 2005-07-13 | 2007-11-01 | Bayer Cropscience Sa | Dihalogenation of N,O-disubstituted hydroxypyridones and their uses |
| WO2007081901A2 (en) | 2006-01-05 | 2007-07-19 | The Scripps Research Institute | Pyrimidinone derivatives as protein kinase inhibitors |
| UY30378A1 (es) | 2006-06-02 | 2008-01-02 | Janssen Pharmaceutica Nv | Nuevos derivados de piridinona n-aril y n-heteroaril sustituidos para usar en enfermedades mediadas por mch-1 |
| WO2008041090A1 (en) * | 2006-10-06 | 2008-04-10 | Pfizer Limited | Malanin concentrating hormone receptor-1 antagonist pyridinones |
| MX2009005449A (es) | 2006-11-24 | 2009-06-02 | Takeda Pharmaceutical | Compuesto heteromonociclico y uso del mismo. |
| CN101595093A (zh) | 2006-12-07 | 2009-12-02 | 诺瓦提斯公司 | 有机化合物 |
| JP2010529129A (ja) | 2007-06-06 | 2010-08-26 | タイロジェネックス，インコーポレイテッド | キナーゼ阻害剤化合物 |
| EA018709B1 (ru) | 2007-07-17 | 2013-10-30 | Бристол-Маерс Сквибб Компани | Пиридоновые агонисты сопряженного с g-белком рецептора gpr119 |
| MX2010014572A (es) | 2008-06-27 | 2011-03-24 | Novartis Ag | Compuestos organicos. |
| WO2011003012A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof |
| US9073925B2 (en) | 2009-07-01 | 2015-07-07 | Albany Molecular Research, Inc. | Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof |
| WO2011003007A1 (en) | 2009-07-01 | 2011-01-06 | Albany Molecular Research, Inc. | Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof |
| US8221753B2 (en) * | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
-
2011
- 2011-12-06 WO PCT/US2011/063608 patent/WO2012078684A1/en not_active Ceased
- 2011-12-06 SI SI201131605T patent/SI2648516T1/sl unknown
- 2011-12-06 CN CN201180066860XA patent/CN103391718A/zh active Pending
- 2011-12-06 ES ES11847595T patent/ES2697607T3/es active Active
- 2011-12-06 HU HUE11847595A patent/HUE040101T2/hu unknown
- 2011-12-06 PL PL11847595T patent/PL2648516T3/pl unknown
- 2011-12-06 HR HRP20181788TT patent/HRP20181788T1/hr unknown
- 2011-12-06 EP EP18192593.4A patent/EP3469907B1/en not_active Not-in-force
- 2011-12-06 DK DK11847595.3T patent/DK2648516T3/da active
- 2011-12-06 CA CA2819889A patent/CA2819889C/en active Active
- 2011-12-06 JP JP2013543290A patent/JP5848775B2/ja not_active Expired - Fee Related
- 2011-12-06 US US13/312,924 patent/US20120142709A1/en not_active Abandoned
- 2011-12-06 EP EP11847595.3A patent/EP2648516B1/en active Active
- 2011-12-06 ES ES18192593T patent/ES2873029T3/es active Active
- 2011-12-06 PT PT11847595T patent/PT2648516T/pt unknown
-
2014
- 2014-01-07 US US14/149,741 patent/US9365547B2/en not_active Expired - Fee Related
- 2014-01-07 US US14/149,659 patent/US9365546B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2819889C (en) | 2020-12-15 |
| US20140171449A1 (en) | 2014-06-19 |
| US20120142709A1 (en) | 2012-06-07 |
| US9365546B2 (en) | 2016-06-14 |
| EP3469907A1 (en) | 2019-04-17 |
| ES2873029T3 (es) | 2021-11-03 |
| HRP20181788T1 (hr) | 2018-12-28 |
| SI2648516T1 (sl) | 2019-01-31 |
| DK2648516T3 (da) | 2019-01-02 |
| HUE040101T2 (hu) | 2019-02-28 |
| EP2648516B1 (en) | 2018-09-05 |
| EP2648516A4 (en) | 2014-04-30 |
| WO2012078684A1 (en) | 2012-06-14 |
| US9365547B2 (en) | 2016-06-14 |
| EP2648516A1 (en) | 2013-10-16 |
| CA2819889A1 (en) | 2012-06-14 |
| PT2648516T (pt) | 2018-11-29 |
| JP5848775B2 (ja) | 2016-01-27 |
| JP2013544889A (ja) | 2013-12-19 |
| US20140171450A1 (en) | 2014-06-19 |
| ES2697607T3 (es) | 2019-01-25 |
| EP3469907B1 (en) | 2021-03-03 |
| CN103391718A (zh) | 2013-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL223783A0 (en) | Pro-neurogenic compounds | |
| GB201008134D0 (en) | Compounds | |
| GB201015949D0 (en) | Compounds | |
| GB201007286D0 (en) | New compounds | |
| GB201020179D0 (en) | New compounds | |
| AP2012006641A0 (en) | New compounds | |
| PL2648516T3 (pl) | Podstawione związki pirydynono-pirydynylowe | |
| PL2619208T3 (pl) | Związki imidazotriazynonu | |
| GB201007347D0 (en) | Compounds | |
| EP2649050A4 (en) | LINKS | |
| GB201002563D0 (en) | Compounds | |
| GB201008209D0 (en) | Compounds | |
| GB201001688D0 (en) | Compounds | |
| GB201002216D0 (en) | Compounds | |
| GB201001796D0 (en) | Compounds | |
| GB201015537D0 (en) | Compounds | |
| GB201008210D0 (en) | Compounds | |
| GB201021494D0 (en) | Compounds | |
| GB201013507D0 (en) | Compounds | |
| GB201001418D0 (en) | Compounds | |
| GB201015757D0 (en) | Compounds | |
| GB201008291D0 (en) | Compounds | |
| GB201013508D0 (en) | Compounds | |
| GB201014052D0 (en) | Compounds | |
| GB201014392D0 (en) | Compounds |